These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7448415)

  • 1. Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments.
    Ratnoff OD
    Blood; 1981 Jan; 57(1):55-8. PubMed ID: 7448415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative amidolytic activity of Hageman factor (factor XII) and its fragments. The effect of high-molecular-weight kininogen and kaolin.
    Ratnoff OD
    J Lab Clin Med; 1980 Aug; 96(2):267-77. PubMed ID: 7400662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid.
    Ratnoff OD; Saito H
    J Lab Clin Med; 1982 Aug; 100(2):248-60. PubMed ID: 7097109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments by popcorn inhibitor.
    Ratnoff OD; Moneme V
    Proc Soc Exp Biol Med; 1981 Feb; 166(2):297-9. PubMed ID: 7208489
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.
    Joist JH; Cowan JF; Khan M
    J Lab Clin Med; 1977 Dec; 90(6):1054-65. PubMed ID: 303667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII).
    Niwano H; Embury PB; Greenberg BD; Ratnoff OD
    J Lab Clin Med; 1995 Feb; 125(2):251-6. PubMed ID: 7844473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4.
    Dumenco LL; Everson B; Culp LA; Ratnoff OD
    J Lab Clin Med; 1988 Sep; 112(3):394-400. PubMed ID: 3045234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hageman factor (factor XII) by popcorn inhibitor.
    Kambhu SA; Ratnoff OD; Everson B
    J Lab Clin Med; 1985 May; 105(5):625-8. PubMed ID: 3989356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q.
    Rehmus EH; Greene BM; Everson BA; Ratnoff OD
    J Clin Invest; 1987 Aug; 80(2):516-21. PubMed ID: 3038961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The regulation of human factor XIIa by plasma proteinase inhibitors.
    Pixley RA; Schapira M; Colman RW
    J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A monoclonal antibody that inhibits activation of human Hageman factor (factor XII).
    Small EJ; Katzmann JA; Tracy RP; Ratnoff OD; Goldsmith GH; Everson B
    Blood; 1985 Jan; 65(1):202-10. PubMed ID: 3965048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the activation of Hageman factor (factor XII) by extracts of Schistosoma mansoni.
    Foster CB; Flanigan TP; DeStigter KK; Blanton R; Dumenco LL; Gallagher C; Ratnoff OD
    J Lab Clin Med; 1992 Nov; 120(5):735-9. PubMed ID: 1431502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
    España F; Ratnoff OD
    J Lab Clin Med; 1983 Oct; 102(4):487-99. PubMed ID: 6604770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the activation of hageman factor (factor XII) by eosinophils and eosinophilic constituents.
    Ratnoff OD; Gleich GJ; Shurin SB; Kazura J; Everson B; Embury P
    Am J Hematol; 1993 Jan; 42(1):138-45. PubMed ID: 8416290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I.
    Henry ML; Everson B; Ratnoff OD
    J Lab Clin Med; 1988 May; 111(5):519-23. PubMed ID: 3361230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that Fitzgerald factor counteracts inhibition by kaolin or ellagic acid of the amidolytic properties of a plasma kallikrein.
    Ratnoff OD; Saito H
    Blood; 1976 Feb; 47(2):243-51. PubMed ID: 1244922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol).
    Laurel MT; Ratnoff OD; Everson B
    J Lab Clin Med; 1992 May; 119(5):580-5. PubMed ID: 1374787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of C1 inhibitor upon Hageman factor autoactivation.
    Weiss R; Silverberg M; Kaplan AP
    Blood; 1986 Jul; 68(1):239-43. PubMed ID: 3487356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.
    Ratnoff OD; Saito H
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):958-61. PubMed ID: 284420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay.
    Kaplan AP; Gruber B; Harpel PC
    Blood; 1985 Sep; 66(3):636-41. PubMed ID: 3875374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.